Amgen says EU CHMP backs broader Repatha use to cut first heart attack, stroke risk - AMGN News | RalliesAmgen says EU CHMP backs broader Repatha use to cut first heart attack, stroke risk
A
AMGN• EU panel backs broader Repatha label
- EMA’s CHMP backed a broader EU label for Amgen’s Repatha to cut cardiovascular risk in adults with established or high-risk atherosclerotic disease.
- Opinion supports use before a first heart attack or stroke, based on the Phase 3 VESALIUS-CV trial in more than 12,000 patients.
- European Commission decision expected in the coming months.
•
